The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Review
PubMed
36977926
PubMed Central
PMC10044103
DOI
10.1038/s41409-023-01955-z
PII: 10.1038/s41409-023-01955-z
Knihovny.cz E-resources
- MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell * therapy MeSH
- COVID-19 * etiology MeSH
- Transplantation, Homologous methods MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Transplantation Conditioning methods MeSH
- Retrospective Studies MeSH
- Hematopoietic Stem Cell Transplantation * methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.
Birmingham Heartlands Hospital Birmingham UK
Bone Marrow Transplant Unit L Copenhagen Denmark
Charles University Hospital Pilsen Czech Republic
CHU de Lille INSERM U1286 Infinite Univ Lille Lille France
Department of Haematology Trinity College Dublin St James's Hospital Dublin Ireland
EBMT Leiden Study Unit Leiden The Netherlands
EBMT Statistical Unit Leiden The Netherlands
Erasmus MC Cancer Institute Rotterdam The Netherlands
Fundació Institut d'Investigació Sanitària Illes Balears IdISBa Palma de Mallorca Spain
Hopital la Pitié Salpêtrière Universite Paris 4 Paris France
Medical Clinic and Policinic 1 Leipzig Germany
Medizinische Klinik m S Hämatologie Onkologie und Tumorimmunologie Berlin Germany
Ospedale San Gerardo Monza Italy
Programme de Transplantation and Therapie Cellulaire Marseille France
Sahlgrenska University Hospital Goeteborg Sweden
St Bartholomew's and The Royal London NHS Trust London UK
Universitaetsklinikum Dresden Dresden Germany
University College London Hospitals NHS Trust London UK
University Department of Hematology Aarhus Denmark
University Hospital Brno Brno Czech Republic
University Hospital Eppendorf Hamburg Germany
University Hospital Essen Germany
University Hospital Maastricht Maastricht The Netherlands
University of Cologne Cologne Germany
University of Heidelberg Heidelberg Germany
See more in PubMed
van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, et al. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia—A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. Clin Lymphoma Myeloma Leuk. 2017;17:667–5.e2. doi: 10.1016/j.clml.2017.06.007. PubMed DOI
Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130:1477–80. doi: 10.1182/blood-2017-04-775841. PubMed DOI
Tournilhac O, Garff-Tavernier ML, Quoc SN, Forcade E, Chevallier P, Legrand-Izadifar F, et al. Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial. Haematologica. 2021;106:1867–75. doi: 10.3324/haematol.2019.239566. PubMed DOI PMC
Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Pract Res Clin Haematol. 2016;29:54–66. doi: 10.1016/j.beha.2016.08.001. PubMed DOI
Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96:1679–705. doi: 10.1002/ajh.26367. PubMed DOI
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020;26:3589–96. doi: 10.1158/1078-0432.CCR-19-3815. PubMed DOI PMC
Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5:4054–8. doi: 10.1182/bloodadvances.2021005083. PubMed DOI PMC
Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132:892–902. doi: 10.1182/blood-2018-01-826008. PubMed DOI
Hoffmann A, Dietrich S, Hain S, Rieger M, Hegenbart U, Sellner L, et al. Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. Haematologica. 2019;104:e304–6. doi: 10.3324/haematol.2018.209486. PubMed DOI PMC
Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4:3977–89. doi: 10.1182/bloodadvances.2020001956. PubMed DOI PMC
Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020;4:4113–23. doi: 10.1182/bloodadvances.2020002184. PubMed DOI PMC
Tournilhac O, Dreger P Chronic Lymphocytic Leukaemia. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook. Cham (CH): Springer; 2022. http://www.ncbi.nlm.nih.gov/books/NBK584167/. PubMed
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6. PubMed DOI PMC
Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, et al. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Front Immunol. 2020;11:594556. doi: 10.3389/fimmu.2020.594556. PubMed DOI PMC
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892–901. doi: 10.1016/S0140-6736(21)00224-5. PubMed DOI PMC
Mato A. Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. In ASH; 2021. https://ash.confex.com/ash/2021/webprogram/Paper147599.html.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors. N Engl J Med. 2022;386:735–43. doi: 10.1056/NEJMoa2114110. PubMed DOI PMC
